Amgen Rises on Strong Q2 Earnings and Raised Guidance

Amgen (NASDAQ:AMGN) shares rose by 3.1% in the afternoon session after the biotech company released its second-quarter 2026 financial results, which exceeded expectations.

The quarterly total revenue increased by 9.5% year-over-year to $10.05 billion, surpassing Wall Street's estimates by 6.9%. The company's adjusted earnings per share of $6.29 also beat consensus forecasts by 12%

Amgen's free cash flow margin improved significantly to 34.7% from 20.8% in the same quarter last year.

In response to the strong performance, Amgen raised its full-year revenue guidance to a midpoint of $38.8 billion and adjusted earnings per share outlook to a midpoint of $22.90.